Yonsei University South Korea
Bioasis Technologies Inc Canada
Nan Bio corporation USA
Biogen Inc USA
Wafa T. Al-Jamal
University of East Anglia UK
EXECUTIVE MEDICAL DIRECTOR, COMBINATION PRODUCT SAFETY HEAD GLOBAL PATIENT SAFETY & PEDIATRICS AMGEN USA
Vladimir P. Torchilin
Northeastern University USA
Eliana Silva de Moraes
President Brazilian Regulatory Affairs France
Recommended Global Pharmaceutical Sciences Webinars & Conferences
Europe & UK
Asia Pacific & Middle East
Pharma Formulations 2023
- Pharmaceutical Formulations & Drug Delivery
- About Pharma Formulations 2023
- Session & Tracks
- Market Analysis
- VISA- TripAdvisor
Pharmaceutical Formulations & Drug Delivery
October 16th - October 17th, 2023 | Toronto, Canada
Conference Series LLC Ltd welcomes you to attend the Pharmaceutical Formulations & Drug Delivery Conference to be held in Toronto, Canada on October 16th - October 17th, 2023. The theme for the conference this year is Successful Formulation Strategies in Achieving Future Generation Advancements .
Details of Pharma Formulations 2023 Conferences in Canada
|Pharma Formulations 2023
|October 16th - October 17th ,2023
About Pharma Formulations 2023
After a successful conference of Pharma Formulations 2022, Pharmaceutical Conferences team cordially invites participants from all over the world to attend " 19th International Conference on Pharmaceutical Formulations & Drug Delivery" (Pharma Formulations 2023) slated on October 16-17, 2023 Toronto, Canada. This Pharmaceutics Conference includes a wide range of Keynote presentations, Oral talks, Poster presentations, Symposia, Workshops, Exhibitions and Career development programs.
Pharma Formulations 2023 covers various aspects of Bio-Pharmaceutics, Pharmaceutical Chemistry Drug Targeting and Design, Pharmacokinetics and Pharmacodynamics in Drugs, Pharmaceutical Formulation, Pharmaceutical Manufacturing, Pharmaceutical Nanotechnology, Novel Drug Delivery Systems, Smart Drug Delivery Systems, Nano medicine and Biomedical Applications, Biomaterials in Drug Delivery, Vaccine Drug Delivery Systems, Medical Devices for Drug Delivery, Biologics & Biosimilars, Pharmaceutical Analysis, Pharmaceutical Process Validation, Pharmaceutical Packaging, Clinical Trials and Clinical Research, Pharmacogenetics and Genomics, Regulatory Affairs and Intellectual Property Rights, Industrial and Physical Pharmacy, Clinical and Hospital Pharmacy, Pharmacovigilance and Drug Safety, Pharmacy Education and Practice
Why you should attend?
- Access to senior-level executives from leading international pharmaceutical & biotechnology companies
- Exposure to new and exciting companies ready for partnerships and licensing opportunities in the U.S., Europe and Asia
- Tremendous networking opportunities to meet numerous U.S., European, Japanese and Asian biotech and pharmaceutical companies in one place at one time
- Use of state-of-the-art partnering technology
- Targeted partner selections through proprietary screening process
- Get to the heart of why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions.
- Discover how advances in the sector are impacting both large and small molecule drugs.
- Explore tried and tested routes to improve bioavailability.
- Understand how to develop the right formulation and delivery strategy with a strong scientific, clinical and commercial mind set.
- Discover the latest innovations in drug delivery devices.
- Be inspired by innovative case studies and realize the potential impact on your formulation or delivery processes.
- Engage in the exciting event format, with round tables, panels, showcases, speed networking and multiple conference tracks.
- Share experiences, insights and strategies in interactive peer to peer round tables.
- Hear more perspectives in one place – from large medium and small organizations from pharma, biotech and academia.
- Discover how scientific formulation advancements are being implemented in practice.
Who Should Attend
- Directors, CEO’s of Organizations
- Business Development Managers
- Chief Scientific Officers
- Professors, Associate Professors, Assistant Professors
- PhD Scholars in Drug Formulation
- PhD in Pharmaceutical Sciences
- Graduates and Post Graduates in Pharmaceutics
- Pharmaceutical Science Professors, Associate Professors, Assistant Professors
- Bio instruments Professionals
- Bio-informatics Professionals
- Supply Chain companies
- Pharmaceutical Manufacturing Companies
- Software development companies
- Drug Formulation Research Institutes and members
- Patent Attorneys
- Intellectual Property Attorneys
- Investment Analysts
- Association, Association presidents and professionals
- Drug development and discovery companies
- Formulation and Pharma Manufacturing companies
- Medical technology companies
- Intellectual property and legal organizations
- Investors and financial services providers
- Bio-clusters and incubators
- Government and public support agencies
Session & Tracks
Increasingly, medicines research is moving from ‘big Pharma’ to small biotech companies and start-ups. To succeed in this new environment, scientific skills are not enough employers and financiers also need to be confident that the people they are working with possess the entrepreneurial skills to grow and sustain a business effectively. Pharmaceutical formulation development enables development of robust and compliant formulations and resolve difficult challenges encountered during preclinical and clinical development.
For developing a new medicine it will take nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.
Track 3: Drug Designing and Development
Researchers discover new drugs through insights into a disease process that allow researchers to design a product to stop or reverse the effects of the disease. Once researchers identify a promising compound for development, they conduct experiments to gather information on how it is absorbed, distributed, metabolized, and excreted, best dosage, Side effects, how it interacts with other drugs and treatments and its effectiveness as compared with similar drugs.
Bringing one new drug to the public typically costs a pharmaceutical or biotechnology company on average more than $1 billion and takes an average of 10 to 15 years. Each drug undergoes a stringent process of discovery, development, approval and finally, public use.
Pharmaceutical excipients have a vital role in formulations. Choosing of excipients is an important in Drug Development. Excipients will have the ideal pharmacokinetic properties. Existing regulations and guidelines indicate that new (novel) excipients should be treated as new chemical entities with full toxicological evaluation. Excipients are now known to have defined functional roles in pharmaceutical dosage forms. Excipients can influence both safety and efficacy outcomes of the drugs. Excipients play a vital role in Drug delivery systems. Excipients are designed to be biologically inactive, removing this barrier could provide a potentially immediate, low-risk solution to the current shortage of new drug formulations.
The global excipient market size is expected to grow to USD 6.9 billion by 2025, a compound annual growth rate (CAGR) of 6.02% from 2017 to 2025.
Track 5: Novel Drug Formulation Procedures
Novel Drug Formulation Procedure is an innovative drug development method which focuses to employ the novel methodologies developed by pharmaceutical industry for a specific intentional use in pharmaceutical Research and development.
Novel drug procedure with unique mechanism offers a much needed treatment option to improve the condition. Bioavailability of the API may be exchanged off when attempting to modify entry of the API due to parts, for instance, gastric upkeep or bypassing the absorptive "window" of the duodenum.
Pharmaceutical nanotechnology is most innovative field in the pharmaceutical industry. Nano technology is dealing with new emerging technologies. Application of nanotechnology in imaging, diagnostics and therapeutics is considered as an important factor. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. Within regulatory boundaries thermodynamics and nanotechnology are considered to be evolving tools to provide new and integrated knowledge for the production of new medicines.
Nanotechnology speaks to a stage for creating progressive changes and enhancements to a wide range of parts of pharmaceutical assembling. Pharmaceutical nanotechnology has provided fine-tuned diagnosis and focused treatment of disease at a molecular level. Nano technology is having an utmost importance in Gene therapy.
Pharmaceutical formulations vary on the route of administration. Eternal formulations prolong the action of duration of drug. Eternal formulation includes tablet, capsule and sustained release dosage forms. Parenteral formulation impacts both the safety and efficacy of drug.
The effect of the dosage form depends on the route of administration. A low medication load may cause homogeneity issues. A high medication load may posture stream issues or require extensive containers if the compound has a low mass thickness.
Bioavailability and Bioequivalence are designed to FDA evaluation of the safety and effectiveness of a product .BA for a given formulation provides an estimate of the relative fraction of the orally 94 administered doses that is absorbed into the systemic circulation. Bioavailability and Bioequivalence mainly focus on the release of a drug substance from a drug. Several in-vitro and in-vivo methods are used to measure the bioavailability of the drugs. For BA and BE studies a single-dose, fasting study be performed. BA studies provide other useful pharmacokinetic information related to distribution, elimination, the effects of nutrients on absorption of the drug, dose proportionality, linearity in pharmacokinetics of the active moieties and, where appropriate, inactive moieties.
Track 9: Pharmaceutical Analysis Methods
For the administration of drugs various chemical and instrumental methods were developed at regular intervals which are involved in the estimation of drugs. Analytical instrumentation and methods play an important role. Different analytical techniques and electrochemical methods like Chromatographic techniques, HPLC, Gas chromatography. From the stages of drug development to marketing and post marketing, analytical techniques play a great role in understanding the physical and chemical stability of the drug, identification of impurities. Analytical techniques are mainly used to determine the safety and efficacy of the drug
Track 10: Challenges in Drug Administration
Medication are used to prevent and illness. Depending upon their site of action and safety and efficacy of drug drugs can be administered through a variety like oral, parenteral, Transdermal, Intradermal etc.. While administering a drug we have to consider the possible side effects and dangerous reactions also. The Dosage of the drug has to be carefully determined. In US, it has been estimated that 80 per cent of active ingredients and 40 per cent of the final drug products are imported. Medicine slant and bolster significance have been surveyed by taking a gander at the self-association of no less than two drugs open under various trial conditions, including choice procedure, dynamic extent fortress timetables, and chain stronghold logbooks.
Track 11: Drug Delivery Technologies
Particle Sciences has a great deal of successful experience in the development of successful delivery systems for many types of APIs and sites of action. Drug delivery technologies enhance drug absorption, efficacy, and patient experience. Enhancing the drug delivery technology of final pharmaceutical formulation can increase its commercial success. Drug delivery systems have been used in delaying drug clearance processes. Drug delivery approaches have their advantages and limitations. Drug delivery approaches include solubilization, permeability enhancement, modified release (MR)
The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period.
Track 12: Novel Drug Delivery Systems
Drug delivery systems control the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity and efficacy of drugs. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms. Novel drug delivery system classified in to different types based on the diffusion types. Drug Delivery Carriers show great promise as drug delivery systems. Drug delivery may be either active or passive process. These are designed to target the site specific region, in order to achieve desired therapeutic effect, thereby reducing the side or toxic effects. NTTD Increases the efficacy of the drug and decrease side effects.
The global market for drug delivery systems is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2021.
Track 13: Wearable Drug Delivery
These are changing the world of drug delivery and preventing the patients from continuous bulk ambulatory devices. Wearable drug delivery device delivers insulin to the wearer. These are developed for dosing a range of drugs such as hormones, analgesics, anti-hypertensives. Large doses 5ml to 50 ml can be comfortably be self-administered by the patient at home by using the Wearable Drug Delivery devices. The life cycle of the product can also be increases. Wearable technology speeds the Formulation and development.
The annual growth rate is expected to reach USD $824 bn by 2025. The size of the market opportunity for LVI devices alone has been estimated at $8.1 billion by 2025, with over 50% of this driven by devices to deliver drugs for cancer and related conditions.
Transdermal Drug Delivery system is an integral part of novel drug delivery system. Drugs having long pharmacokinetic half-lives are considered to be Unsuitable for transdermal application. By the increased number of marketing authorization applications together with recent scientific developments for transdermal patches, the need for clear guidance on specific requirements for this dosage form increased.
The emergence of technological innovations in transdermal patches is expected to provide the market with lucrative growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.
Track 15: Drug Delivery approaches for Parenterals
Parenteral Drug Delivery has been developed alternative to the normal route of administration. The success depends on clinical as well as on patient compliance. This route is mainly used for the drugs having poor aqueous solubility and this route improves the patient compliance and decreases the systemic availability. Chitosan is used as micro particles, liposomes, granules, and gels for oral and parenteral drug delivery. Parenteral administration route is the most common for delivery of active drug substances with a narrow therapeutic index. This route of administration may cause less cardiac attacks and respiratory attacks. Parenteral delivery still remains the major mode of administration for protein and peptide therapeutics
A new class of drug delivery device which can inject doses far larger than today’s syringes or auto injectors has developed i.e., Bolus Injectors having the capability to deliver more than 1 ml of a drug subcutaneously in a simple, reliable, and inexpensive manner. In the last 12 years, drugs have been delivered using self-regulated and Nano-technology systems. The manufacturers need to consider clinical guidelines and regulatory requirements governing combination products also differ from both pharmaceuticals and medical devices.
To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other nonprofit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.
Development of a new pharmaceutical product requires at least 15 years because of changes in the regulatory. Regulatory Affairs Department acts as the interface between the pharmaceutical company and the regulatory agencies across the world. Regulatory authorities act a vital role for approval of generics.
Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. Regulatory Affairs professionals can play a key role in guiding drug development strategy in an increasingly global environment.
North America and Europe contribute about 57.0% of global pharmaceutical sales. The global regulatory affairs outsourcing market size was valued at USD 4.53 billion in 2016 and is expected to grow at a CAGR of 11.9% over the forecast period.
The global pharmaceutical manufacturing market was valued at USD 405.52 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028. This growth is driven by the emergence of new technologies, cost-effective manufacturing approaches, and increasing investment flow in the pharmaceutical sector. The implementation of robotic technology and Artificial Intelligence (AI) has reduced manufacturing floor downtime and product waste.
The pharmaceutical drug delivery market was estimated to be worth $1,656.9 billion in 2021 and is expected to reach $2,206.5 billion by 2026, growing at a CAGR of 5.9% from 2021 to 2026. The growth in this market can be attributed to the rising prevalence of chronic diseases, the growing biologics market, increasing R&D investments, technological advancements, and new product launches.
The pharmaceutical industry has seen a shift from large batches to smaller batches for the development of complex medicines and autologous patient-centric treatments1. The conventional drugs (small molecules) segment accounted for the highest revenue share of over 65% in 20201. Biologics are gaining significant attention due to substantial investments and innovative approaches.
The outsourcing segment dominated the market in 2020 with a revenue share of over 54%. Outsourced services minimize the investments, reduce drug development & overall costs, increase the efficiency of manufacturing procedures, and easily comply with different regulatory norms.
The infectious diseases segment accounted for the largest share of the global pharmaceutical drug delivery market in 2020. The home care settings segment is projected to grow at the highest CAGR during the forecast period. North America accounted for the largest share of this market in 2020.
In conclusion, the pharmaceutical formulations and drug delivery market is experiencing significant growth due to technological advancements, increasing R&D investments, and the rising prevalence of chronic diseases. The market is expected to continue its upward trajectory in the coming years.
Planning a Trip to Vancouver, Canada!!! Attending Meeting!!!
An issue with VISA!!
Pharma Formulations 2023 Committee will be happy to help you in all regards to plan your trip to Vancouver, Canada. Avail the official invitation letter from us to attend this event ahead with a closer step for approval of your VISA.
Find out what you need to do to visit Canada as a tourist or business person, how to extend your stay in Canada and what documents you need to carry with you to transit through Canada.
Canada does not have a visa office in every country so it is important that Delegates/Attendees visit the website of the visa office responsible for processing their visa applications. Information is available on the website on how to submit a visa application and the documentation required.
This system allows clients to submit applications online.
Delegates/Attendees that need a visa but require their passport for other travel purposes are strongly encouraged to submit their visa applications online (e-Apps). Delegates/Attendees that choose to apply online will not have to submit their passport until a decision has been taken on their applications. If required, the visa office will send the applicant instructions on how and where to send their passports to finalize the visa process.
Visa Application Centers (VACs):
VACs are commercial service providers authorized by Canada to provide specific services to applicants.
VACs provide a number of services including help applicants fill out forms, answer questions and ensure that applications are complete, thereby reducing unnecessary delays or refusals due to incomplete applications.
Applicants that are required to provide biometrics information as part of the visa application process can do so at a VAC. Additional information on the biometrics requirements is available at the IRCC website.
VACs send applications to Visa Offices and transmit decisions to applicants in a secure and confidential manner. VACs do not process visa applications and play no role in the decision-making process.
Visa Applications Processing Time:
Processing time for visa applications vary depending on the office and the time of the year. Participants should be encouraged to apply early for their visas, and to submit complete applications including all supporting documents.
Please visit the IRCC website for information on the time it takes to process visa applications at the various visa offices.
NEW - Electronic Travel Authorization (eTA)
As of March 15, 2016, visa-exempt foreign nationals are expected to have an Electronic Travel Authorization (eTA) to fly to or transit through Canada. Exceptions include U.S. citizens and travelers with a valid Canadian visa. Canadian citizens, including dual citizens, and Canadian permanent residents are not eligible to apply for an eTA.
However, from March 15, 2016, until fall 2016, travellers who do not have an eTA can board their flight, as long as they have appropriate travel documents, such as a valid passport. During this time, border services officers can let travellers arriving without an eTA into the country, as long as they meet the other requirements to enter Canada. We invite you to consult the IRCC website regularly for information updates on eTA.
Best Tourist Destination: Vancouver
- Stanley Park
- Granville Island
- Grouse Mountain
- Museum of Anthropology
- Kitsilano Beach
- Canada Place
- English Bay
- Capilano Suspension Bridge
- Robson Street
- Museum of Vancouver
- Queen Elizabeth Park
- Science World
- Richmond & Many more…
Past Conference Report
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by